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Sphingosine 1-phosphate (S1P), a pleiotropic lipid mediator,
binds to five related G-protein-coupled receptors to exert its
effects. As S1P1 receptor (S1P1R) activation blocks kidney
inflammation in acute renal injury, we tested whether
activation of S1P1Rs ameliorates renal injury in early-stage
diabetic nephropathy (DN) in rats. Urinary albumin excretion
increased in vehicle-treated diabetic rats (single injection of
streptozotocin), compared with controls, and was associated
with tubule injury and increased urinary tumor necrosis
factor-a (TNF-a) at 9 weeks. These effects were significantly
reduced by FTY720, a non-selective, or SEW2871, a selective
S1P1R agonist. Interestingly, only FTY720 was associated
with reduced total lymphocyte levels. Albuminuria was
reduced by SEW2871 in both Rag-1 (T- and B-cell deficient)
and wild-type diabetic mice after 6 weeks, suggesting that
the effect was independent of lymphocytes. Another
receptor, S1P3R, did not contribute to the FTY720-mediated
protection, as albuminuria was also reduced in diabetic
S1P3R knockout mice. Further, both agonists restored WT-1
staining along with podocin and nephrin mRNA expression,
suggesting podocyte protection. This was corroborated
in vitro, as SEW2871 reduced TNF-a and vascular endothelial
growth factor mRNA expression in immortalized podocytes
grown in media containing high glucose. Whether targeting
kidney S1P1Rs will be a useful therapeutic measure in DN will
need direct testing.
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Diabetes mellitus and diabetic nephropathy (DN) are
disorders that result, in part, from a dysregulation of the
immune system. Proinflammatory markers such as tumor
necrosis factor-a (TNF-a), interleukin-6, and C-reactive
protein in patients with DN suggest that chronic low-grade
inflammation is a characteristic of DN.1–3 Activated
T-lymphocytes have been associated with DN and correlated
with initiation of early-stage proteinuria in type 1 and type 2
diabetes.4,5 Infiltration of CD4þ and CD8þ T cells, as well
as overexpression of major histocompatibility complex class I
and II molecules, on lymphocytes may have an important
role in the pathogenesis of both immune-mediated and non-
immune-mediated inflammatory kidney disease associated
with DN.6 These findings point to the role of chronic mild
inflammation and T cells in the pathogenesis of DN.
Sphingosine 1-phosphate (S1P), a pleiotropic lipid
mediator, is produced by phosphorylation of sphingosine
by sphingosine kinases (SphKs; SphK1, and SphK2) in
response to a variety of stimuli. S1P binds to five related
G-protein-coupled receptors, termed S1P1–5Rs.7 S1P recep-
tors regulate a wide variety of important cellular functions,
including cell survival, cytoskeletal rearrangements, and cell
motility.7,8 We and others have shown that S1P1 receptors
(S1P1Rs) are expressed in kidneys as well as on bone-
marrow-derived cells, and on activation reduce inflamma-
tion.9,10 FTY720, a non-selective S1P1R agonist, and
SEW2871, a selective S1P1R agonist, elicit lymphopenia
resulting from reversible redistribution of lymphocytes from
the circulation to secondary lymphatic tissue.11,12 FTY720 is a
pro-drug and is phosphorylated by SphK1 and SphK2 into its
active form.13 Notably, previous studies demonstrated a
remarkable protective effect of FTY720 in models of multiple
sclerosis,13,14 autoimmune myocarditis,15 uveoretinitis,16
systemic lupus erythematosus,17 and atherosclerosis.18
FTY720 prevents autoimmune diabetes in non-obese diabetic
mice by preventing the development of hyperglycemia and
insulinitis.19–21 However, these studies mainly focused on the
effect of FTY720 on the pancreas. In humans, FTY720 has
been shown to be efficacious in relapsing multiple sclerosis,22
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and has been recently approved by the Food and Drug
Administration for the treatment of multiple sclerosis.
We have demonstrated that activation of S1P1Rs protects
the kidney by reducing inflammation, leukocyte infiltration,
and vascular permeability associated with acute renal
ischemia–reperfusion injury, primarily by peripheral lym-
phocyte depletion or direct effects on kidney cells expressing
S1P1Rs.9,23 Whether FTY720 or other S1P1R agonists have an
effect to reduce inflammation, proteinuria, and histological
changes associated with DN is not known. Because
lymphocytes may contribute to early-stage proteinuria,4,5
we hypothesized that activation of S1P1Rs would ameliorate
renal tissue injury associated with early-stage DN. Using
streptozotocin (STZ)-induced rat and mouse animal models,
we show that chronic S1P1R activation by FTY720 or
SEW2871 prevents functional and structural changes induced
by diabetes by ameliorating urinary albumin excretion
(UAE), urinary TNF-a, podocyte-specific proteins, podocyte
TNF-a and vascular endothelial growth factor (VEGF)
mRNA expression, and tubule vesicular injury and vacuoliza-
tion. The mechanism(s) by which FTY720 and SEW2871
reduce the functional and morphological changes induced by
diabetes appear(s) to be independent of lymphocytes, and is
likely mediated primarily by S1P1Rs and not by S1P3Rs. To
our knowledge, this study provides for the first time evidence
of the protective role of S1P1R agonists in DN and
demonstrates that targeting kidney S1P1Rs may be a novel
therapeutic intervention in the treatment of DN.
RESULTS
Effects of FTY720 and SEW2871 on blood glucose, body
weight, systolic blood pressure, and urinary volume in rats at
9 weeks were studied. Blood glucose levels increased
significantly in the diabetes groups treated with vehicle,
FTY720, or SEW2871 throughout the study period (Table 1).
Control rats gained weight as expected. The increase in body
weight in vehicle- and drug-treated diabetic groups was
modest, and body weight in diabetic groups was markedly
lower than control rats at week 9. There was a significant
increase in urinary volume in diabetic groups. There were no
significant changes in systolic blood pressure at 9 weeks after
STZ induction of diabetes in any group.
Effects of FTY720 and SEW2871 on renal function in diabetic rats
As expected, diabetic rats treated with vehicle showed a
significant progressive increase in UAE that began as early as
3 weeks after STZ, continued at week 6, and peaked at week 9.
Both FTY720 and SEW2871 significantly reduced UAE at
week 6 and at week 9, compared with vehicle (Figure 1).
Effects of FTY720 and SEW2871 on renal histology in DN
Masson’s trichrome stain of rat kidneys from control rats
(Figure 2a and e), diabetic rats treated with vehicle (Figure 2b
and f), and diabetic rats treated with FTY720 (Figure 2c and g)
or SEW2871 (Figure 2d and h) at week 9 of the study was
used to evaluate renal histology. Diabetic rats treated with
vehicle (Figure 2b and f) had severe tubular injury associated
with vacuolization (tubular injury score, 3.4±0.4; Po0.0001,
n¼ 5) compared with control (score, 0.2±0.1, n¼ 7), with
slight interstitial fibrosis. Both FTY720 and SEW2871
significantly reduced these histological effects (score
2.3±0.5, n¼ 6 and 2.2±0.3, n¼ 9, respectively; Po0.05
compared with vehicle).
Effects of FTY720 and SEW2871 on urinary TNF-a production
Inflammatory cytokines have an important role in DN.
Therefore, we assessed the anti-inflammatory effect of
FTY720 and SEW2871 treatment on urinary TNF-a level in
diabetic rats. Urinary TNF-a excretion increased significantly
in the vehicle-treated diabetic rats at week 9, and this increase
was reduced by treatment with either FTY720 or SEW2871
administration (Figure 3).
Table 1 | Changes in blood glucose, body weight, systolic
blood pressure (BP), and urinary volume in control, vehicle-
treated diabetic rats, and diabetic rats treated with FTY720
or SEW2871 for 9 weeks
Control
Diabetes +
vehicle
Diabetes +
FTY720
Diabetes +
SEW2871
Blood glucose (mg/dl)
Week 0 81±4 78±2 80±4 80±5
Week 3 77±4 326±16* 321±28* 333±8*
Week 6 89±5 334±24* 390±12* 418±30*,w
Week 9 88±7 465±22* 354±18*,w 414±29*
Body weight (g) 514±15 264±28* 285±13* 268±8*
Systolic BP (mmHg) 135±3 136±2 138±3 138±2
Urinary volume
(ml per 24 h)
14±1 41±4* 33±4* 39±6*
Data are mean±s.e.m. *Po0.001 compared to control; wPo0.05 compared to
diabetes + vehicle.
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Figure 1 | FTY720 and SEW2871 reduce urinary albumin
excretion in diabetic rats. To determine the effect of FTY720 and
SEW2871 in diabetic rats, 24-h urine collections were obtained for
measurement of urine albumin at baseline (W0) and at weeks (W)
3, 6, and 9 of the study. Open bars, control group; black bars,
vehicle-treated diabetes group; dark gray bars, diabetes group
treated with FTY720 (0.3mg/kg, oral gavage); and light gray bars,
diabetes group treated with SEW2871 (0.1mg/kg, i.p.). Data are
means±s.e.m. *Po0.05, **Po0.005 and ***Po0.0005 compared
with control; þPo0.05, þþPo0.01 and þþþPo0.005 compared
with vehicle-treated diabetes group.
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Effects of FTY720 and SEW2871 on kidney tissue content of T
cells, B cells, and macrophages in diabetes
As S1P1R activation has been shown previously to reduce
peripheral blood and tissue lymphocyte count,11,12,24 we
investigated whether the protective effect of FTY720 and
SEW2871 in diabetes is mediated by lymphopenia. As shown
in Table 2, fluorescence-activated cell sorting analysis
revealed no significant effects of FTY720 or SEW2871
treatment compared with vehicle on the kidney content of
T cells, B cells, or macrophages in diabetic rats. In contrast,
FTY720 but not SEW2871 treatment significantly reduced
blood lymphocyte count in diabetic rats (Table 2).
Effects of SEW2871 on UAE in Rag-1 diabetic mice
We further questioned whether the effect of S1P1R agonist
was mediated, at least in part, by inducing lymphopenia in
the STZ-induced diabetic model. Therefore, we used Rag-1
mice (which lack T- and B cells) and wild-type (WT) mice.
As shown in Figure 4, UAE was increased significantly by
STZ-induced diabetes in WT and Rag-1 mice. SEW2871
treatment significantly reduced UAE in diabetic WT group
and was associated with reduced lymphocyte count
(0.36±0.1K/ml; Po0.01) from vehicle-treated diabetes group
(1.27±0.2 K/ml). SEW2871 still reduced UAE in diabetic
Rag-1 mice.
S1P3Rs do not contribute to the FTY720 protective effect
in DN
FTY720 is a non-selective S1P1R agonist, and it may activate
other S1P receptors such as S1P3R, S1P4R, and S1P5R. We
have shown previously that, of the five subtypes, S1P1R and
S1P3R have the highest expression in the kidney.9 To examine
the relative contribution of these two receptor subtypes to
FTY720 effect in DN, we induced diabetes in mice deficient
in S1P3Rs (S1P3/) and their corresponding WT littermate
S1P3þ /þ controls. FTY720 significantly reduced UAE in
STZ-treated S1P3/ mice (Figure 5).
S1P1R agonists regulate podocyte-specific proteins
To determine the possible mechanisms by which FTY720 and
SEW2871 reduce UAE and mediate renal tissue protection,
Figure 2 | FTY720 and SEW2871 improve renal histology in
diabetic nephropathy. Masson’s trichrome staining of kidney
sections from normal control rat (a, e), diabetic rat treated with
vehicle (b, f), and a diabetic rat treated with FTY720 (c, g) or
SEW2871 (d, h) at 9 weeks of the study. Representative
photographs show extensive tubular damage with vacuolization
(arrows), interstitial fibrosis (blue staining of interstitial collagen),
and increased intertubular space (arrowhead) in vehicle-treated
diabetic rats and minimal changes in treated animals. Bar¼ 50mm.
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Figure 3 | FTY720 and SEW2871 reduce urinary tumor necrosis
factor-a (TNF-a) level. Urine collections (24-h) were obtained for
measurement of TNF-a in rats after 9 weeks of streptozotocin
(STZ)-induced diabetes. Open bar, control group; filled bar,
vehicle-treated diabetes group; hatched bar, diabetes group
treated with FTY720 (0.3mg/kg, oral gavage); and gray bar,
diabetes group treated with SEW2871 (0.1mg/kg, i.p.). Values are
means±s.e.m. *Po0.05, **Po0.01, and ***Po0.005 compared
with control; þPo0.05 and þþPo0.01 compared with vehicle-
treated diabetes group.
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we examined their effects on podocytes. At 9 weeks of
diabetes, both nephrin and podocin (podocyte-specific
proteins) mRNA were significantly reduced and were
associated with reduced number of WT-1-positive staining
(16.2±1.2 cells; Po0.0001) in kidneys from vehicle-treated
diabetic rats compared with control (WT-1-positive staining:
30±1 cells). FTY720 and SEW2871 restored and markedly
increased the expression of nephrin and podocin in diabetic
rats and increased the number of WT-1-positive staining
(28±1 cells, Po0.0001; 22±2 cells, Po0.05), respectively,
compared with vehicle (Figure 6). These data suggest that
FTY720 and SEW2871 could have direct effects on podocytes.
To explore this option, first, we examined the expression of
S1P receptors and S1P synthetic enzymes in podocytes. We
have shown previously that S1P1-4Rs but not S1P5Rs are
expressed in kidney, with S1P1Rs having the highest receptor
expression.9 We also showed that both SphK1 and SphK2 are
expressed in the kidney.25 We now extend these findings and
show mRNA expression of S1P1–4Rs, but not of S1P5R
(Figure 7a), and of SphK1 and SphK2 (Figure 7b) in an
immortalized mouse podocyte cell line, indicating a possible
role of endogenous S1P in podocytes under physiological or
pathophysiological conditions. To explore this possibility, we
cultured immortalized podocytes with normal glucose or
high glucose (HG) media for 14 days. Our data show
enhanced TNF-a and VEGF mRNA expression after HG
media, an effect significantly reduced using SEW2871
treatment (Figure 7c and d). In contrast, there were no
effects on podocyte apoptosis (data not shown) in all groups.
DISCUSSION
This study demonstrates a finding previously unrecognized
that FTY720 and SEW2871 have protective effects on renal
function and histology in an STZ-induced diabetic rat model.
The effect of S1P1R activation in diabetes is probably not due
to lymphocyte depletion, as SEW2871 continues to induce
renal tissue protection in Rag-1 mice that lack both T and B
cells. Furthermore, FTY720 effects are mediated mainly
through S1P1R activation, as FTY720 was protective in
S1P3/ mice. FTY720 or SEW2871, either directly by
maintaining podocyte-specific proteins and expression of
TNF-a and VEGF or indirectly, control glomerular perme-
ability and podocyte function. Additionally, we observed
marked reduction of tubule injury and vacuolization,
suggesting effects of these compounds on proximal tubule
cells. Because progressive kidney disease due to DN results
from abnormalities of the glomerulus and the tubulointer-
stitium, the broad ranging effects of S1P1R agonists might be
more effective than current therapies for DN.
Table 2 | Effects of FTY720 and SEW2871 on blood
lymphocyte count and kidney tissue content of T cells, B cells,
and macrophages in diabetes
Method
Diabetes +
vehicle
Diabetes +
FTY720
Diabetes +
SEW2871
CD3 FACSa 1.1±0.3 0.6±0.3 2.0±0.3
CD8 FACS 0.5±0.1 0.3±0.1 0.7±0.2
CD4 FACS 1.4±0.3 0.7±0.2 2.5±0.7
CD45R FACS 0.6±0.3 0.2±0.1 0.3±0.1
CD11b FACS 0.7±0.1 0.8±0.04 2.9±0.5
Lymphocyte HEMAVETb 4.3±0.7 2.5±0.5* 4.5±0.7
Abbreviations: HEMAVET, veterinary hematology system; FACS, flow cytometry
analysis.
aKidney tissue content of T cells (CD3+, CD8+, CD4+), B cells (CD45R+), and
macrophages (CD11b+) was determined by FACS (no of cells 104) after 9 weeks in
diabetic rats.
bBlood lymphocyte count (K/ml: 1000/ml) was determined by using HEMAVET.
*Po0.05 compared with vehicle-treated diabetic rats.
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Figure 4 | SEW2871 reduces urinary albumin excretion (UAE)
in Rag-1 diabetic mice. Urine collections were obtained for
measurement of UAE at week 6 in wild-type (WT) and Rag-1 mice
after streptozotocin (STZ)-induced diabetes. Open bars, control
group; black bars, vehicle-treated diabetes group; and gray bars,
diabetes group treated with SEW2871 (1mg/kg, i.p.). Data are
means±s.e.m. *Po0.05 and **Po0.01 compared with control;
þPo0.05 compared with vehicle-treated diabetes group. Blood
glucose (BG) values are shown below the bars for each group.
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Figure 5 | FTY720 reduces albuminuria independent of
sphingosine 1-phosphate 3 receptor (S1P3R) effects. Urine
collections were obtained for measurement of urinary albumin
excretion (UAE) at week 4 in S1P3þ /þ (wild type, WT) and
S1P3/ mice after streptozotocin (STZ)-induced diabetes. Open
bars, control group; black bars, vehicle-treated diabetes group;
and gray bar, diabetes group treated with FTY720 (0.3mg/kg, oral
gavage). Data are means±s.e.m. *Po0.05 compared with control;
þPo0.05 compared with vehicle-treated diabetes group. Blood
glucose (BG) values are shown below the bars for each group.
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The biological functions of S1P have been explored in
diverse cell types and tissues. However, the exact role of S1P
in kidney physiology and pathophysiology remains unclear.
S1P regulates a wide variety of important cellular func-
tions.7,8 S1P1Rs are expressed in the kidney,9,26 and have an
important role in maintaining endothelial cell integrity27,28
and in trafficking of lymphocytes.29
Recently, we demonstrated that both FTY720 and
SEW2871 prevent renal ischemia–reperfusion injury by
activating S1P1Rs.9,23 Our current study extends the role of
S1P1Rs from an acute to a chronic model of DN. In this
study, we demonstrated a significant increase in UAE after 3
weeks of diabetes in conscious rats, which persisted
throughout the study period. Administration of FTY720 or
SEW2871 significantly reduced albuminuria associated with
diabetes. The effect of S1P1R activation was associated with
marked reduction of tubular injury and vacuolization in DN.
It is now clear that DN is a tubule–glomerular disorder.
Whether S1P1R activation has a direct effect on tubular cells
in DN is not clear in this study. However, data from our
laboratory show that S1P1R activation mediates renal tissue
protection through a direct effect on proximal tubule S1P1Rs
in renal ischemia–reperfusion injury.23 It is possible that
tubular cell injury associated with DN contributes, in part, to
increased UAE in diabetes and that S1P1R activation reduced
albuminuria by protecting tubular injury. Additional study is
needed to explore the direct effect of S1P1R activation on
tubular cells in DN. Furthermore, the reduction of podocyte
mRNA expression of VEGF after SEW2871 treatment of
immortalized podocytes following HG suggests that the
effects of S1P1R agonists on reducing proteinuria early in the
course of diabetes may be mediated by a direct effect on
podocytes.
We have shown previously that levels of urinary TNF-a
were correlated with increases in UAE in diabetes.30 TNF-a is
produced mainly by monocytes/macrophages, T and B
lymphocytes, and glomerular mesangial cells.31,32 Both
TNF-a and interleukin-1b have been associated with
increased vascular endothelial permeability33 and have been
detected in isolated glomerular basement membrane in
diabetes.34 It is possible that S1P1R activation by FTY720
or SEW2871 protects kidneys in DN by reducing kidney
inflammatory cytokines such as TNF-a. The fact that TNF-a
was undetectable in the blood30 indicates that the source of
urinary TNF-a was mainly from the kidney. Interestingly,
neither FTY720 nor SEW2871 affected the number of
kidney macrophages, as shown by fluorescence-activated cell
sorting, suggesting that their effects are mainly mediated
through kidney-derived cells producing TNF-a. Our data in
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Figure 6 | Sphingosine 1-phosphate 1 receptor (S1P1R)
agonists regulate podocyte-specific proteins. (a, b) Reverse
transcriptase-PCR (RT-PCR) was performed on whole rat kidney
total RNA isolated after 9 weeks of diabetes from control, vehicle-
treated diabetic (D) rats, and diabetic rats treated with FTY720 or
SEW2871. (a) Gel analysis of PCR products. (b) Expression of
nephrin and podocin mRNA was normalized to glyceraldehyde
3-phosphate dehydrogenase (GAPDH) and data were calculated
as expression relative to control. Black bars, vehicle-treated
diabetic rats; dark gray bars, diabetic rats treated with FTY720
(0.3mg/kg, oral gavage); and light gray bars, diabetic rats treated
with SEW2871 (0.1mg/kg, i.p.). Data are means±s.e.m. *Po0.05,
**Po0.005 compared with control (dashed line); þPo0.05,
þ þPo0.01 compared with vehicle-treated diabetes group.
(c–f) WT-1 staining of rat kidney after 9 weeks of diabetes from
control (c), vehicle-treated diabetic (d) rats, and diabetic rats
treated with FTY720 (e) or SEW2871 (f) (magnification  400).
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podocytes support this hypothesis and show that SEW2871
reduced podocyte mRNA expression of TNF-a after HG.
Another observation from our study indicates that SEW2871
treatment elicits more kidney macrophage recruitment than
the vehicle group. These data are consistent with a recent
report indicating that an increase in the percentage and
absolute number of circulatory monocytes in response to
SEW2871 treatment occurs by enhanced monocyte emigra-
tion from the bone marrow.35
The mechanism by which S1P1R agonists mediate
protection in STZ-induced DN is not completely clear.
Previous reports showed that S1P1R activation induces
lymphopenia resulting from a reversible redistribution of
lymphocytes from the circulation to secondary lymphatic
tissue.11,12,36 Therefore, we questioned whether FTY720 and
SEW2871 have a similar effect in diabetes. Our data show
that FTY720, but not SEW2871, reduced elevated blood
lymphocyte counts that occurred in diabetic rats. These
studies suggested that S1P1R agonists mediate their effect
independent of lymphocytes. To test this hypothesis, we
examined the effect of SEW2871 at doses known to induce
lymphopenia in mice that lack T- and B lymphocytes (Rag-1)
and found that even in the absence of lymphocytes, SEW2871
reduced albuminuria. These results raise the possibility that
S1P1R agonists mediate their protective effect independent of
their canonical effect on lymphocytes and may induce direct
effects to alter glomerular permeability. Our data demon-
strating direct effects of SEW2871 on cultured podocytes are
consistent with this hypothesis.
FTY720 is rapidly phosphorylated in vivo by SphKs to
form FTY720 phosphate, which is an agonist for S1P1R and
S1P3–5Rs, but not for S1P2R,11,13 and mediates the
immunosuppressive effect of FTY720.11,13 Therefore, the
relative contributions of different actions of FTY720 may
depend on tissue expression of receptor subtypes. Both
S1P1R and S1P3R are highly expressed in the kidney.9 S1P1R
activation mediates cell survival and proliferation of vascular
endothelial cells, as well as stimulation of endothelial cell
nitric oxide synthase.27,37 These effects on endothelial cells
may lead to maintenance of endothelial barrier function. We
have shown previously that FTY720 is necessary to maintain
vascular integrity after ischemia–reperfusion injury.9 Whether
the protective effect of FTY720 and SEW2871 is due to action
on kidney endothelial cells cannot be answered by our study,
but will require additional investigation. In contrast to
S1P1R, S1P3R activation is thought to lead to a loss of
epithelial integrity in the lung38 and may have a similar
function in the kidney. Therefore, we questioned whether
S1P3Rs are involved in FTY720 protective effects in DN. Our
data clearly show that FTY720 still reduced UAE in diabetic
S1P3/ mice. This excludes any possible role of S1P3R to
mediate FTY720 effects in DN and provides additional
evidence that the effect of FTY720 is mainly mediated
through S1P1R activation.
We further investigated a possible mechanism of S1P1R
activation in DN. As podocytes have a pivotal role in
maintaining the glomerular filtration barrier, we questioned
whether podocytes either directly or indirectly mediate
S1P1R agonist effect. Our data demonstrate that FTY720
and SEW2871 restored both nephrin and podocin mRNA
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Figure 7 |Role of sphingosine 1-phosphate 1 receptor (S1P1R)
agonists in immortalized podocytes in vitro. (a, b) Total RNA
from immortalized podocytes was extracted and subjected to
analysis by reverse transcriptase-PCR (RT-PCR) for S1P receptor
mRNA expression (a) and sphingosine kinase 1 and 2 (SphK1 and
SphK2) mRNA expression (b). (c, d) Total RNA from immortalized
podocytes subjected to normal glucose (NG) or high glucose (HG)
media for 14 days with or without SEW2871 (n¼ 5–6 each group)
was extracted and subjected to analysis by RT-PCR for tumor
necrosis factor-a (TNF-a) mRNA expression (c) and vascular
endothelial growth factor (VEGF) mRNA expression (d). Expression
of TNF-a and VEGF mRNA was normalized to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). Open bars, NG; black bars,
HG treated with vehicle; and gray bars, HG treated with SEW2871
(1 mmol/l). Data are means±s.e.m. *Po0.05, **Po0.01 compared
with NG; þPo0.05 compared with HG þ vehicle.
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expression and ameliorated the reduction in WT-1-positive
staining after 9 weeks of diabetes, indicating a potential direct
or indirect role of S1P1R activation on kidney cells such as
podocytes. Both podocin and nephrin are crucial complex
proteins in the assembly and reinforcement of the slit
diaphragm by binding to the actin cytoskeleton.39,40
Dysregulation of these podocyte structural proteins has been
associated with glomerular injury in diabetes.30,41,42
Recently, we demonstrated a rank order of expression of
S1P1R4S1P3R4S1P2R4S1P4R in mouse kidneys, whereas
S1P5R mRNA was not found.9 In addition, both SphK1 and
SphK2 are expressed in the kidney.25 In this study, we further
confirmed the expression of S1P1R and the S1P biosynthetic
enzymes, SphK1 and SphK2, on podocytes, indicating a
possible direct site of action for FTY720 and SEW2871 on
podocytes in diabetes and that S1P may have a role, possibly
autocrine, in podocytes under physiological or pathophysio-
logical conditions. Treatment with FTY720 or SEW2871 did
not change S1P1R expression in diabetes (data not shown);
therefore, S1P1R agonists likely act by increasing S1P1R
signaling. In addition, these data provide evidence that
chronic administration of FTY720 or SEW2871 does not
downregulate S1P1Rs. To investigate the direct role of
S1P1R agonist in podocytes, we carried out in vitro
experiments in immortalized podocytes grown in culture
and treated with HG. Our data show that SEW2871 reduced
the induction of podocyte mRNA expression of TNF-a and
VEGF after HG, indicating a direct effect of S1P1R agonist in
podocytes.
In summary, this study extends our previous observations
of the protective effect of S1P from an acute to a chronic
diabetic model and demonstrates that chronic administration
of S1P1R agonists attenuates renal dysfunction in early-stage
DN. We believe that the renal tissue protective effect of
S1P1R agonist is not mediated by inducing lymphopenia, but
may have a direct effect on kidney-derived cells such as
podocytes. We conclude that S1P1R activation may represent
a novel therapeutic option for the treatment of early-stage
diabetic kidney disease.
MATERIALS AND METHODS
Induction of diabetes
Experiments were conducted in 14-week-old conscious Sprague–-
Dawley rats (Charles River Laboratories, Wilmington, MA) weigh-
ing 240–260 g. Additional experiments were conducted in 7- to
8-week-old C57BL/6J and Rag-1 mice (B6 background; Jackson
Laboratories, Bar Harbor, ME) and in mice that lack S1P3R;
S1P3/ mice (congenic on C57BL/6) or S1P3þ /þ mice (littermate
controls) were provided by Dr Richard L Proia (National Institutes
of Health). All experiments were performed in accordance with the
NIH and the Institutional Animal Care and Use Guidelines, and all
protocols and procedures were approved by the University of
Virginia Animal Care and Use Committee. After an overnight fast,
animals were given a single intravenous injection via tail vein of
vehicle or STZ (Sigma, St Louis, MO; rats 50mg/kg body weight and
mice 80mg/kg body weight; dissolved in lactated Ringer solution).
Establishment of diabetes was confirmed 48 h after STZ induction
by measuring random blood glucose levels (Accu-Chek glucometer,
Boehringer Mannheim, Indianapolis, IN).
Drug delivery
A 1mmol/l stock solution of FTY7209,13 (Novartis, Basel, Switzer-
land) or SEW28719 was prepared in a 3% fatty acid-free bovine
serum albumin (Sigma)/phosphate-buffered saline solution. For rat
experiments, FTY720 was given at a dose of 0.3mg/kg by oral gavage
and SEW2871 at a dose of 0.1mg/kg (i.p.) daily, Monday through
Friday (n¼ 6–8 each group), for 9 weeks. For Rag-1 mouse
experiments, SEW2871 was given at a dose of 1mg/kg (i.p.) daily,
Monday through Friday (n¼ 4 each group), for 6 weeks. For S1P3R
experiments, FTY720 was given at a dose of 0.3mg/kg by oral gavage
daily, Monday through Friday (n¼ 4 each group), for 4 weeks.
Administration of S1P agonists or vehicle (3% fatty acid-free bovine
serum albumin/phosphate-buffered saline solution) started on the
same day as STZ administration.
Podocyte cell culture
All experiments were carried out on differentiated immortalized
mouse podocyte cell line (1 105 cells/well) kindly provided by
Dr John Sedor (Case Western Reserve University, Cleveland, OH) in
six-well collagen-coated culture dishes for 14 days, as previously
described.43 Differentiated podocytes were then exposed to RPMI
media containing either 11mmol/l D-glucose (normal glucose) or
33mmol/l D-glucose (HG), with or without vehicle or SEW2871
(1mmol/l), for 14 days after differentiation. Medium was replaced
three times per week.
Renal histology
Kidneys from rats were fixed in 4% paraformaldehyde and
embedded in paraffin, and 4-mm sections were cut. Sections were
stained with Masson’s trichrome, hematoxylin and eosin, and
Periodic acid-Schiff stains. Sections were examined (WKB) in a
masked manner under  400 magnification by light microscopy
(Zeiss AxioSkop, Thornwood, NY) for mesangial expansion,
interstitial fibrosis, and tubular injury. Semiquantitative scores
(0 to 4þ ) were assigned based on the masked reading, as previously
described.30 For WT-1 staining, sections were stained with rabbit
polyclonal IgG (dilution 1:300; Santa Cruz Biotechnology, Santa
Cruz, CA) as we described previously.43 A total of 20 glomeruli/
kidney were selected randomly and the number of WT-1-positive
cells of the entire glomerulus was counted in a masked manner.
Quantitative real-time PCR
Total RNAwas extracted from rat kidneys and from podocytes using
RNeasy Mini Kit (Qiagen, Gmbh, Hilden, Germany). Single-strand
cDNA was synthesized using iScript cDNA Synthesis Kits (Bio-Rad,
Hercules, CA) for two-step real-time RT-PCR. Gene-specific
primers for nephrin, podocin, S1P1-5R, SphK1, SphK2, TNF-a,
and VEGF were designed using Beacon Designer Probe/Primer
Design Software (Premier Biosoft International, Palo Alto, CA;
Table 3). Primers were obtained from Integrated DNA Technologies
(Coralville, IA). Specificity of the PCR products was verified by
melting curve analysis followed by gel electrophoresis. Quantitative
real-time PCR was performed using a MyIQ Single-Color Real-Time
PCR Detection System iCycler (Bio-Rad, Hercules, CA). Reactions
were performed in duplicate, and threshold cycle numbers were
averaged. Samples were calculated with normalization to glycer-
aldehyde 3-phosphate dehydrogenase, as described previously.30
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Fluorescence-activated cell sorting analysis
We used flow cytometry to analyze kidney leukocyte content for T
cells (CD4, CD3, and CD8), B cells (CD45R), and macrophages
(CD11b) in vehicle-treated, FTY720-treated, or SEW287-treated
diabetes groups at the end of the study as described previously.9 In
brief, kidneys were extracted, minced, digested, and then passed
through a filter and a cotton wool column. Fresh kidney suspensions
were incubated with anti-rat CD45-fluorescein isothiocyanate (30-
F11) for 30min on ice. Anti-rat CD45 was used to determine the
total leukocyte cell number. The remaining sample was stained for
T cells, B cells, and macrophages, as previously described.
7-aminoactinomycin D was added 15min before running the
sample to exclude dead cells. Subsequent flow cytometry data
acquisition was performed on FASCalibur (Becton Dickinson, San
Jose, CA). Data were analyzed by FlowJo software 6.4 (Tree Star,
Ashland, OR). All the antibodies were purchased from eBioscience
(San Diego, CA). For measurement of apoptosis, cultured podocytes
were washed with cold phosphate-buffered saline and resuspended
in 1 binding buffer (BD Pharmingen, San Diego, CA); 100 ml of
cells were incubated with 5 ml of fluorescein isothiocyanate-
conjugated Annexin V and 3 ml of 7-aminoactinomycin D for
15min at room temperature in the dark. The reaction was stopped
by addition of 400 ml of 1 binding buffer, and cells were analyzed
by fluorescence-activated cell sorting.
Analytical methods
Urinary albumin was measured by ELISA using a Nephrat kit for
rats or Albuwell M kit for mice (Exocell, Philadelphia, PA), as
described previously.30 Anticoagulated blood was analyzed for
leukocyte counts (HEMAVET 850, CDC Technologies, Oxford,
CT).9 Urine TNF-a was measured by ELISA (BD Pharmingen).30
Systolic blood pressure was measured via the tail-cuff method (IITC
model 179, IITC/Life Science Instruments, Woodland Hills, CA), as
described previously.30
Statistical analysis
For the comparisons among groups, we used analysis of variance,
with adjusting for multiple comparisons by applying the Tukey’s
method or the Wilcoxon’s test, depending on the distribution of
data. To take into account repeated measurement, PROC MIXED
procedure in SAS was invoked to compare urine albumin for
diabetic group over the weeks. All analyses were performed in
SAS 9.2 statistical software (SAS Institute, Arlington, VA), and the
two-sided P-values o0.05 were considered significant.
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